Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Apr
21
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Elisrasib Demonstrates High DCR in KRAS G12C NSCLC
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo